Apexigen Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Apexigen is a clinical-stage biotechnology company focused on developing antibody-based cancer therapeutics, emphasizing immuno-oncology approaches that aim to harness the patient’s immune system to fight tumors. Its lead candidate sotigalimab is a CD40-activating antibody currently in Phase 2 development. The company is based in San Carlos, California, and operates as a small biotechnology firm within the biotechnology research sector pursuing a new generation of antibody therapies for cancer. Its work targets cancer patients and the clinical research community evaluating immuno-oncology approaches, often in collaboration with academic medical centers such as Columbia University. A Phase 2 study of sotigalimab with doxorubicin in advanced soft tissue sarcoma, presented at ASCO 2023, reported indications of improved overall survival and progression-free survival, with an expansion cohort for dedifferentiated liposarcoma underway.